Evidence-Based Medicine
Primary Ovarian Insufficiency (POI)
Background
- Primary ovarian sufficiency (POI) refers to hypergonadotropic hypogonadism in women before age 40 years.
- POI results from depletion or dysfunction of ovarian follicles due to genetic, iatrogenic, autoimmune, or idiopathic causes.
- POI presents with delayed or absent menarche or oligo/amenorrhea in addition to other symptoms of menopause, such as hot flashes and vaginal dryness.
- Untreated it results in a number of complications including osteoporosis, hypercholesterolemia, cardiovascular disease, impaired sexual function, and impaired well-being.
Evaluation
- Suspect diagnosis of primary ovarian insufficiency in adolescents with normal sexual characteristics who have not reached menarche by age 15 years, and women aged < 40 years with amenorrhea for ≥ 4 months or < 9 menses per year and symptoms of estrogen deficiency.
- Exclude pregnancy as a cause of amenorrhea (Strong recommendation).
- Measure follicle stimulating hormone (FSH) and estradiol twice, at least 1 month apart. Diagnosis is confirmed with the presence of FSH levels > 40 units/L and estradiol level < 50 pg/mL (Strong recommendation).
- Other tests to consider when primary ovarian insufficiency is suspected include thyroid-stimulating hormone (TSH), prolactin, luteinizing hormone (LH), karyotype evaluation to detect X chromosome abnormalities, and genetic screening to detect premutation of the FMR1 gene.
- For women who wish to become pregnant, consider ovarian reserve tests (ORT) to determine oocyte reserve and quality (Weak recommendation).
Management
- Offer either hormone replacement therapy or combination oral contraceptives until the typical age of natural menopause (Strong recommendation).
- Testosterone therapy can be considered to improve libido and sexual function in women with surgically-induced menopause, however androgen treatment is supported by limited data and women should be advised that long-term health effects are unclear (Weak recommendation).
- Use nonhormonal contraceptive methods (for example, barrier methods) for women who do not desire to become pregnant (Strong recommendation). Oral contraceptives will not prevent ovulation and pregnancy.
Published: 08-07-2023 Updeted: 08-07-2023
References
- De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010 Sep 11;376(9744):911-21
- Cordts EB, Christofolini DM, Dos Santos AA, Bianco B, Barbosa CP. Genetic aspects of premature ovarian failure: a literature review. Arch Gynecol Obstet. 2011 Mar;283(3):635-43
- Torrealday S, Kodaman P, Pal L. Premature Ovarian Insufficiency - an update on recent advances in understanding and management. F1000Res. 2017;6:2069
- European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI., Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37